We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Sertraline for Premenstrual Dysphoric Disorder

Lee S. Cohen, MD
JAMA. 1998;279(5):357-358. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-5-jbk0204.
Text Size: A A A
Published online


To the Editor.— The multicenter study by Dr Yonkers and colleagues1 reported the efficacy of sertraline hydrochloride for patients with premenstrual dysphoric disorder (PMDD). The results of this study are consistent with 6 prior reports of the efficacy of fluoxetine in similar populations.1,2 The authors selected sertraline as an alternative to fluoxetine for treatment of PMDD in part because it "can be started at a low dose." Yet, with respect to initiating treatment, fluoxetine can certainly be first administered at low doses, eg, 10 mg. The authors also speculate that the short half-life of sertraline makes it preferable for women who wish to conceive or who inadvertently conceive. Although the more rapid clearance of sertraline from maternal circulation following documentation of pregnancy offers a potential advantage with respect to limiting total time of fetal exposure,3 nearly 50% of women who conceive do so inadvertently and present well into the first trimester.4 At this point, fetal exposure to sertraline is of concern given the dearth of systematic information regarding the safety of this agent during pregnancy. In contrast, there are 1100 prospectively studied cases of first trimester exposure to fluoxetine and no evidence of increased teratogenic risk.3 Postmarketing surveillance study of fluoxetine exposure during pregnancy now includes approximately 1900 cases. Unfortunately, there are no available systematic postmarketing surveillance registers for sertraline.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.